Navigation Links
bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Date:1/31/2012

around time for the test results was important in their clinical decisions.  Our lab will respond to our client's needs by providing PRECIS test results within 7 to 10 days," Ding concluded.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin and PRECIS Precision Medicine by bioTheranostics, which includes clinically relevant oncology biomarkers for comprehensive cancer management.

For more information, call 1-858-587-5870 or visit www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached euro 1.427 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and
'/>"/>

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. bioTheranostics Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
2. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
3. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
4. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
5. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
6. Neogen Launches Fully Quantitative Lateral Flow Test for DON
7. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
8. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
11. Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Dr. Pollard Brings the Highest Level of Clinical ... Feb. 1 Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical ... patented,immunotherapeutic platform technology, announced that it has appointed,Richard ... Dr. Pollard has been a leader in HIV/AIDS ...
... N.J., Feb. 1 Amicus Therapeutics,Inc. (Nasdaq: FOLD ... Executive Officer, will present a corporate update at the ... York, NY on Thursday, February 7, 2008 at 11:40 ... The presentation will be webcast live and may be ...
... 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... of common stock at a price of $27.00,per share. ... The underwriters,have an option to purchase up to an ... is expected to close on February 6,2008, subject to ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 3Rigel Announces Pricing of Public Offering of Common Stock 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... PHILADELPHIA -- Scientists are another step closer to ... there are factors inside tumors that can slow their ... Cancer Research , a journal of the American Association ... researcher at the division of experimental medicine at the ...
... A recent study led by researchers at Boston University School ... mortality among patients diagnosed with severe sepsis and new-onset atrial ... assistant professor of medicine at BUSM and a pulmonologist at ... study, which will be published in the Journal of the ...
... SAN FRANCISCO Combining the investigational agents REGN910 ... effects in animal models compared with either agent ... International Conference: Molecular Targets and Cancer Therapeutics, held ... findings suggest that combining REGN910 (SAR307746) and aflibercept ...
Cached Biology News:BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death 2Combination therapy shows potent tumor growth inhibition in preclinical studies 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: